Obalon Therapeutics Inc. (OBLN)
Company Description
Obalon Therapeutics, Inc., a vertically integrated medical device company, focuses on developing and commercializing medical devices to treat people with obesity.
The company offers the Obalon Balloon System designed to provide weight loss in patients with obesity.
Its Obalon Balloon System comprises of a swallow able capsule that contains an inflatable balloon attached to a microcatheter; the Obalon Navigation System console, which is a combination of hardware and software used to track and display the location of the balloon during placement; the Obalon Touch Inflation Dispenser, which is a semi-automated, hand-held inflation device used to inflate the balloon once it is placed; and a disposable canister filled with mixture of gas.
As of February 27, 2020, it had three company-managed retail treatment centers in California.
Obalon Therapeutics, Inc. was founded in 2008 and is headquartered in Carlsbad, California.

Country | United States |
IPO Date | Oct 6, 2016 |
Industry | Medical - Devices |
Sector | Healthcare |
Employees | 2 |
CEO | Kelly Huang |
Contact Details
Address: 5421 Avenida Encinas Ste F Carlsbad, California United States | |
Website | http://www.obalon.com |
Stock Details
Ticker Symbol | OBLN |
Exchange | NASDAQ |
Fiscal Year | January - December |
Reporting Currency | USD |
CIK Code | 0001427570 |
CUSIP Number | 67424L209 |
ISIN Number | US67424L2097 |
Employer ID | 00-0000000 |
SIC Code | 3841 |
Key Executives
No executives data available.Latest SEC Filings
Date | Type | Title |
---|---|---|
Jul 03, 2025 | 8-K | Current Report |
Jun 26, 2025 | 425 | Filing |
Jun 24, 2025 | 424B3 | Filing |
Jun 18, 2025 | 8-K | Current Report |
Jun 17, 2025 | POS AM | Filing |
Jun 13, 2025 | SCHEDULE 13G | Filing |
Jun 12, 2025 | 8-K | Current Report |
Jun 09, 2025 | 424B5 | Filing |
Jun 09, 2025 | 8-K | Current Report |
Jun 06, 2025 | 424B3 | Filing |